What are the effects of Nadolol (beta blocker) on patients with liver failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Nadolol should be used with caution in patients with liver failure, and dose reduction is recommended, as its use can lower arterial pressure, decrease survival time, and increase the risk of paracentesis-induced circulatory dysfunction in patients with refractory ascites, as noted in the 2020 guidelines for liver cirrhosis 1. When using nadolol in patients with liver failure, it is essential to consider the potential risks and benefits, as the medication can have adverse effects such as bradycardia, hypotension, and bronchospasm.

  • The initial dose should be reduced by 30-50% of the normal starting dose (typically 20-40 mg daily instead of 40-80 mg), with careful titration based on clinical response.
  • Regular monitoring of heart rate, blood pressure, and clinical status is crucial when using nadolol in these patients.
  • If signs of beta-blocker toxicity develop (severe bradycardia, hypotension, bronchospasm), the dose should be reduced or the medication discontinued.
  • Alternative beta-blockers with minimal hepatic metabolism, such as atenolol, might be considered in severe liver failure cases. The use of nonselective beta-blockers (NSBBs) in patients with liver failure is still a topic of controversy, with some studies suggesting that they may be associated with a higher likelihood of poor outcomes, as noted in the 2021 practice guidance by the American Association for the Study of Liver Diseases 1.
  • However, it is essential to weigh the potential benefits of NSBBs, such as reducing the risk of variceal bleeding, against the potential risks, and to carefully monitor patients for any adverse effects.
  • The "window period" hypothesis suggests that NSBBs may only be useful during a certain period in the natural history of cirrhosis, and that their use beyond that time may be detrimental 1. Overall, the use of nadolol in patients with liver failure requires careful consideration of the potential risks and benefits, and close monitoring of patients for any adverse effects.

From the Research

Effects of Nadolol on Patients with Liver Failure

  • The effects of nadolol, a beta blocker, on patients with liver failure are not entirely clear, but some studies provide insight into its impact on liver function and patient outcomes 2.
  • A study published in 1988 found that long-term treatment with nadolol did not significantly impair liver function in patients with cirrhosis, as measured by quantitative liver function tests 2.
  • However, another study from 1997 notes that drugs dependent on liver metabolism, like nadolol, may accumulate in patients with liver disease, leading to excessive plasma concentrations and potential adverse effects 3.
  • In contrast, carvedilol, another beta blocker, has been shown to have a more favorable profile in patients with liver disease, with improved survival and reduced risk of decompensation in patients with compensated and decompensated cirrhosis 4, 5.
  • The pharmacokinetics of nadolol in patients with liver disease are not well-studied, but it is known that the drug is metabolized by the liver, and its bioavailability may be increased in patients with liver disease 6.

Comparison with Carvedilol

  • Carvedilol has been compared to nadolol and other non-selective beta blockers in patients with cirrhosis, and has been found to have a more favorable efficacy and safety profile 4, 5.
  • A study published in 2024 found that carvedilol reduced the risk of decompensation and mortality in patients with compensated and decompensated cirrhosis, compared to non-selective beta blockers like nadolol 4.
  • Another study from 2019 found that treatment with carvedilol improved survival and reduced the risk of acute kidney injury and spontaneous bacterial peritonitis in patients with acute-on-chronic liver failure 5.

Clinical Implications

  • The use of nadolol in patients with liver failure should be approached with caution, given the potential for accumulation and adverse effects 3.
  • Carvedilol may be a preferred option for patients with liver disease, given its more favorable efficacy and safety profile 4, 5.
  • Further studies are needed to fully understand the effects of nadolol and other beta blockers on patients with liver failure, and to determine the optimal treatment strategies for these patients 3, 4, 2, 5.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is acotiamide safe for a patient with liver disease and how should the dose be adjusted according to the severity of hepatic impairment (Child‑Pugh A, B, or C)?
Is the current regimen of ceftriaxone, pantoprazole, ondansetron, furosemide (Dytor), spironolactone (Aldactone) and propranolol (Inderol) with the given dosing frequencies appropriate for an 80‑year‑old female with a urinary‑tract infection, metabolic‑associated fatty liver disease with esophageal varices, hypertension, diabetes, presenting with hematuria and vomiting, and labs showing severe anemia, thrombocytopenia, mild renal impairment, hyponatremia, hyperglycemia, elevated bilirubin, hypoalbuminemia and coagulopathy?
What antibiotics are contraindicated in patients with liver failure?
Is it appropriate to add mirtazapine (Remeron) to the medication regimen of a patient in their late 30s with a history of cirrhosis, normal liver function tests (LFTs), and currently managed with quetiapine (Seroquel) 150 mg, clonidine (Clonodine) 0.2 mg, and desvenlafaxine (Pristiq) 100 mg for persistent insomnia?
Is Mounjaro (tirzepatide) safe for weight loss in a patient with liver cirrhosis and esophageal varices?
Can Clonazepine (Klonopin) cause altered mental status?
Can Clonazepine (Klonopin) cause altered mental status?
What are the current recommendations for Antiretroviral Therapy (ART) prophylaxis for infants of Human Immunodeficiency Virus (HIV)-positive mothers, both high-risk and low-risk?
What is the significance of a dilute Russell viper venom time (dRVVT) of 42 seconds?
What is the significance of a prolonged Activated Partial Thromboplastin Time (APTT) of 38 seconds, indicative of Lupus Anticoagulant sensitivity?
Is there an interaction between minoxidil and chemotherapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question